Literature DB >> 26919560

The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis.

Zhexue Qin1, Bin Cui1, Jun Jin1, Mingbao Song1, Baoshang Zhou2, Hongfeng Guo3, Dehui Qian1, Yongming He1, Lan Huang4.   

Abstract

AIMS: The ubiquitin-activating enzyme E1 (UBA1, E1), the apex of the ubiquitin proteasome pathway, plays a critical role in protein degradation and in pathological processes. Whether UBA1 participates the development of vascular restenosis remains unknown. This study aims to determine the role of UBA1 in the development of balloon injury induced neointimal formation. METHODS AND
RESULTS: Immunostaining and western blots were used to examine the expression of the ubiquitinated protein in the injured carotid after angioplasty. Higher levels of ubiquitinated protein were observed in the neointima. Local delivery of potent chemical UBA1 inhibitor PYR-41 (100 μM) and UBA1 shRNA lentivirus both resulted in a substantial decrease in intimal hyperplasia at 2 weeks and 4 weeks after balloon injury. UBA1 inhibition also reduced Ki-67 positive cell percentage and inflammatory response in the carotid artery wall. We further determined that in vitro UBA1 inhibition was able to ameliorate TNF-α-induced nuclear factor-kappa B (NF-κB) activation by reducing IκB degradation in vascular smooth muscle cells (VSMCs). UBA1 inhibition also led to the accumulation of short-lived proteins such as p53, p21 and c-jun, which may account for the UBA1 inhibition-induced cell cycle delay. Thus, VSMCs proliferation was blocked.
CONCLUSIONS: UBA1 inhibition effectively suppresses neointimal thickening through its anti-proliferative and anti-inflammatory effects. Our results provide further evidence that the ubiquitin-proteasome system is a potential new target for the prevention of vascular restenosis.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Inflammation; Restenosis; Ubiquitin-activating enzyme E1; Vascular injury

Mesh:

Substances:

Year:  2016        PMID: 26919560     DOI: 10.1016/j.atherosclerosis.2016.02.016

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Comparative proteomic analysis identifies differentially expressed proteins and reveals potential mechanisms of traumatic heterotopic ossification progression.

Authors:  Zhenyuan Wei; Shang Guo; Hongwei Wang; Yang Zhao; Jiren Yan; Chi Zhang; Biao Zhong
Journal:  J Orthop Translat       Date:  2022-05-14       Impact factor: 4.889

2.  Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells.

Authors:  Gerrit Müller; Charlotte Lübow; Günther Weindl
Journal:  Autophagy       Date:  2019-11-07       Impact factor: 16.016

3.  Downregulation of Cavin-1 Expression via Increasing Caveolin-1 Degradation Prompts the Proliferation and Migration of Vascular Smooth Muscle Cells in Balloon Injury-Induced Neointimal Hyperplasia.

Authors:  Li-Jun Zhou; Xue-Ying Chen; Shui-Ping Liu; Lin-Lin Zhang; Ya-Nan Xu; Pan-Wei Mu; Deng-Feng Geng; Zhi Tan
Journal:  J Am Heart Assoc       Date:  2017-07-27       Impact factor: 5.501

4.  SAK-HV Decreases the Self-Ubiquitination of MEKK1 to Promote Macrophage Proliferation via MAPK/ERK and JNK Pathways.

Authors:  Chao Zhang; Yao Chen; Xiangdong Gan; Zhiguang Huang; Minji Zou; Wenliang Fu; Weiwei Xing; Donggang Xu
Journal:  Int J Mol Sci       Date:  2017-04-19       Impact factor: 5.923

5.  Inhibition of the Ubiquitin-Activating Enzyme UBA1 Suppresses Diet-Induced Atherosclerosis in Apolipoprotein E-Knockout Mice.

Authors:  Jiawei Liao; Xiaolei Yang; Qiuyue Lin; Shuang Liu; Yunpeng Xie; Yunlong Xia; Hui-Hua Li
Journal:  J Immunol Res       Date:  2020-03-20       Impact factor: 4.818

6.  Cysteine-Rich LIM-Only Protein 4 (CRP4) Promotes Atherogenesis in the ApoE-/- Mouse Model.

Authors:  Natalie Längst; Julia Adler; Anna Kuret; Andreas Peter; Peter Ruth; Karsten Boldt; Robert Lukowski
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.